EP3981768A4 - Polymorph von cdk9-inhibitor und herstellungsverfahren für polymorph und verwendung davon - Google Patents

Polymorph von cdk9-inhibitor und herstellungsverfahren für polymorph und verwendung davon Download PDF

Info

Publication number
EP3981768A4
EP3981768A4 EP20819010.8A EP20819010A EP3981768A4 EP 3981768 A4 EP3981768 A4 EP 3981768A4 EP 20819010 A EP20819010 A EP 20819010A EP 3981768 A4 EP3981768 A4 EP 3981768A4
Authority
EP
European Patent Office
Prior art keywords
polymorph
manufacture
cdk9 inhibitor
cdk9
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20819010.8A
Other languages
English (en)
French (fr)
Other versions
EP3981768A1 (de
Inventor
Fusheng ZHOU
Jinzhu ZHAO
Jiong Lan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Original Assignee
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc, Zhejiang Genfleet Therapeutics Co Ltd filed Critical Genfleet Therapeutics Shanghai Inc
Publication of EP3981768A1 publication Critical patent/EP3981768A1/de
Publication of EP3981768A4 publication Critical patent/EP3981768A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
EP20819010.8A 2019-06-06 2020-06-05 Polymorph von cdk9-inhibitor und herstellungsverfahren für polymorph und verwendung davon Pending EP3981768A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910489946 2019-06-06
PCT/CN2020/094527 WO2020244612A1 (zh) 2019-06-06 2020-06-05 Cdk9抑制剂的多晶型物及其制法和用途

Publications (2)

Publication Number Publication Date
EP3981768A1 EP3981768A1 (de) 2022-04-13
EP3981768A4 true EP3981768A4 (de) 2023-07-12

Family

ID=73653127

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20819010.8A Pending EP3981768A4 (de) 2019-06-06 2020-06-05 Polymorph von cdk9-inhibitor und herstellungsverfahren für polymorph und verwendung davon

Country Status (9)

Country Link
US (2) US12384774B2 (de)
EP (1) EP3981768A4 (de)
JP (1) JP7314319B2 (de)
KR (1) KR102886764B1 (de)
CN (1) CN113966332B (de)
AU (1) AU2020288270B2 (de)
BR (1) BR112021024506A2 (de)
CA (1) CA3142444C (de)
WO (1) WO2020244612A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270658B (zh) * 2023-05-24 2023-10-27 劲方医药科技(上海)有限公司 Cdk9抑制剂与btk抑制剂联用的药物组合及其用途
WO2024239512A1 (zh) * 2023-05-22 2024-11-28 劲方医药科技(上海)有限公司 药物组合及其在治疗癌症中的用途
CN116270644A (zh) * 2023-05-22 2023-06-23 劲方医药科技(上海)有限公司 Cdk9抑制剂与bcl-2抑制剂联用的药物组合及其用途
WO2025217597A1 (en) 2024-04-12 2025-10-16 Sellas Life Sciences Group, Inc. A cdk9 inhibitor for use in the treatment of cancer in a subject having an asxl1 mutation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613737A1 (de) * 2017-04-19 2020-02-26 Genfleet Therapeutics (Shanghai) Inc. Neuartiger inhibitor der cyclin-abhängigen kinase cdk9

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (de) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. Hochdurchsatzherstellung sowie bestimmung und analyse verschiedener fester formen
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
CN103298787A (zh) 2010-11-17 2013-09-11 诺瓦提斯公司 3-(氨基芳基)-吡啶化合物
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613737A1 (de) * 2017-04-19 2020-02-26 Genfleet Therapeutics (Shanghai) Inc. Neuartiger inhibitor der cyclin-abhängigen kinase cdk9

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEILEI WANG ET AL: "Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 158, 1 October 2018 (2018-10-01), AMSTERDAM, NL, pages 896 - 916, XP055714086, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.09.025 *
MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5 *
See also references of WO2020244612A1 *

Also Published As

Publication number Publication date
US20260015347A1 (en) 2026-01-15
EP3981768A1 (de) 2022-04-13
CA3142444C (en) 2025-02-11
JP2022535870A (ja) 2022-08-10
US20220315576A1 (en) 2022-10-06
CA3142444A1 (en) 2020-12-10
CN113966332B (zh) 2024-07-30
US12384774B2 (en) 2025-08-12
WO2020244612A1 (zh) 2020-12-10
CN113966332A (zh) 2022-01-21
BR112021024506A2 (pt) 2022-01-18
JP7314319B2 (ja) 2023-07-25
AU2020288270B2 (en) 2023-07-13
KR102886764B1 (ko) 2025-11-14
AU2020288270A1 (en) 2022-02-03
KR20220016949A (ko) 2022-02-10

Similar Documents

Publication Publication Date Title
EP3943496A4 (de) Wee1-inhibitor sowie herstellungsverfahren und verwendung davon
IL292754A (en) Method of synthesis
IL287787A (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287795A (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP4524135A4 (de) Kinesin-kif18a-hemmer und verwendung davon
EP4069212A4 (de) Inhibitoren von hif-2alpha
EP3572400A4 (de) Ezh2-inhibitor und verwendung davon
EP3981768A4 (de) Polymorph von cdk9-inhibitor und herstellungsverfahren für polymorph und verwendung davon
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
EP3983386A4 (de) Acss2-hemmer und verfahren zur verwendung
EP3755690A4 (de) Egfr-hemmer und verfahren zur verwendung davon
EP3565520A4 (de) Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
EP3741752A4 (de) Tam-kinase- und csf1r-kinase-inhibitor und verwendung davon
EP4509505A4 (de) Kif18a-hemmer und verwendung davon
HRP20260295T1 (hr) Kristalni oblici inhibitora btk
EP4072436A4 (de) Heftgerät und verfahren zur verwendung
EP3728268A4 (de) Nek-hemmer und verfahren zur verwendung
EP3741758A4 (de) Bromdomäneninhibitorverbindung und verwendung davon
EP3941909A4 (de) Pi4-kinase-inhibitoren und verfahren zur verwendung davon
EP3754021A4 (de) Aptamer für sclerostin und verwendung davon
EP3897622A4 (de) Arginase-inhibitoren und verfahren zur verwendung
EP4333821A4 (de) Inhibitoren von sars-cov-2
EP3744722A4 (de) Ss-lactamase-hemmer und verwendung davon
EP4058015A4 (de) Allosterische egfr-inhibitoren und verfahren zur verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230614

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230607BHEP

Ipc: A61K 31/4439 20060101ALI20230607BHEP

Ipc: C07D 417/14 20060101AFI20230607BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250409